#AI Technology #Drug Design #Fathom Therapeutics

Fathom Therapeutics Secures $47 Million in Series A Funding

In a significant boost for the pharmaceutical sector, Fathom Therapeutics, formerly known as Atommap Corp., has successfully raised $47 million in an oversubscribed Series A financing round. This funding, led by Sutter Hill Ventures, aims to propel the company's groundbreaking work in drug molecule design using quantum chemistry and AI technologies.

Founded by a team of experts including Huafeng Xu, PhD (CEO), Yujie Wu, PhD (CTO), and Jesus Izaguirre, PhD (Chief Computational Scientist), Fathom Therapeutics is at the forefront of revolutionizing traditional drug discovery methodologies. The company’s proprietary platform, Microcosmos, leverages advanced algorithms to simulate protein behavior at an atomic level, allowing for accurate predictions of how drug molecules will interact within living cells.

Dr. Xu noted that the current methods in drug discovery largely depend on static models of isolated proteins, which can limit creativity in developing new therapeutics. By translating precise quantum mechanical calculations into observable cellular outcomes, Microcosmos aims to create small molecules that can effectively modify protein behavior, targeting previously deemed